myMedidata Patient Portal

myMedidata is a web-based patient portal that covers the full functionality of Medidata solutions. Among other things, it is used to obtain consent electronically and to evaluate clinical outcomes (electronic clinical outcomes assessment, eCOA), as well as to video-communicate researchers and patients using myMedidata LIVE, through an intuitive web interface. With myMedidata, patients can use any device with Internet access for virtual learning, enrollment, and trial participation.

2021: Announcement myMedidata Registries

On June 28, 2021, Medidata, owned by Dassault Systèmes, introduced myMedidata Registers, a technology that expands the potential of the myMedidata portal. It is designed to work more effectively with patients in the initial and post-clinical phases of research (i.e., long-term follow-up at the end of the process/safety oversight ). With myMedidata Registers, users will be able to learn more about the possibilities of such tests, and will also be directly involved throughout the process. Given the growing interest in decentralized clinical research as of June 2021, as well as the increase in their number, myMedidata Registers will be an appropriate solution to support patients both immediately during and after the analysis. This is possible due to access to a single portal covering all the needs during the tests and ensuring continuous interaction of the participants in the process.

myMedidata

According to the company, for many years there have been problems in the industry related to the lack of patient awareness and the difficulties of providing access to clinical research. This situation negatively affected the decision of many people to take part in the tests. According to the Center for Information and Study on Clinical Research Participation (CISCRP), as of June 2021, only 25% of respondents are "fully confident" in the ability to find the necessary clinical study data. Also, 98% of survey participants announced their readiness to undergo another study. However, many of them reported that they never received feedback after completing the process, whether it was results, returning patient data, a letter of thanks, or an invitation to participate in another trial. Thus, work with these respondents does not continue, and the procedure for recruiting participants is repeated each time.

The launch of myMedidata Registers took place more than ever by the way. The community needed a simple way to participate in clinical research. And here's what I want to say: don't miss the opportunity - the more people participate, the faster we can get scientific data to better understand the nature of diseases and how to treat them. told Anne Marie Mercurio, patient rights advocate, nursing specialist and member of the Medidata's Patient Insights team

myMedidata Registries is based on Medidata Clinical Cloud, a unified technology platform for clinical research. With it, you can tell patients about the trial, as well as perform preliminary screening and data collection. In addition, it provides for the possibility of video acquaintance before the patient goes to the medical center or is included in the list of participants. Clinical research funders and contract research organizations with myMedidata Registries gain the ability to communicate directly and securely with participants through notifications and warnings.

myMedidata Registries was first introduced in the United States and will soon be launched in a number of other countries. It provides sponsors with a single unified ecosystem for identifying patients, conducting research and interacting with them upon their completion. In addition, it provides for the possibility of returning patient data. Once a therapeutic, vaccine or medical device is on the market, myMedidata Registers allows funders and contract research organizations to continue working with study participants. This is necessary when long-term monitoring (LTFU) and product safety profile monitoring is required. Regulators are requesting long-term analysis data for thousands of studies, and human gene therapy trials require observations for 15-30 years or more. In addition, myMedidata Registries can be used in the transition of patients from phase 2 and 3 to phase 4 clinical trials.

The creation of myMedidata Registers was carried out in partnership with the Medidata Patient Insights team. Medidata experts in their work rely on the philosophy of Patient Centrality by Design (PCbD). The consequence is that the software development cycle considers any processes in terms of patient interests.